<DOC>
	<DOCNO>NCT00004884</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know whether docetaxel plus gemcitabine effective docetaxel plus cisplatin treating advance pancreatic cancer . PURPOSE : Randomized phase II trial compare effectiveness docetaxel gemcitabine docetaxel cisplatin treat patient metastatic locally advanced pancreatic cancer .</brief_summary>
	<brief_title>Docetaxel Gemcitabine Compared With Docetaxel Cisplatin Treating Patients With Metastatic Locally Advanced Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess efficacy docetaxel gemcitabine v docetaxel cisplatin patient metastatic locoregionally advanced pancreatic cancer . II . Assess toxicity , response rate , duration response , time progression , survival , performance status , weight associate treatment regimens patient . OUTLINE : This randomize , open label , multicenter study . Patents randomize one two treatment arm . Arm I : Patients receive gemcitabine IV 30 minute day 1 8 docetaxel IV 1 hour day 8 . Arm II : Patients receive docetaxel IV 1 hour follow cisplatin IV 1 hour day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients follow every 6 week disease progression , every 8 week death . PROJECTED ACCRUAL : Up 82 patient ( 41 per arm ) accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic locoregionally advanced ( metastatic lymph node ) unresectable adenocarcinoma exocrine pancreas Bidimensionally measurable disease outside previously irradiate field No CNS involvement leptomeningeal disease PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) Renal : Creatinine great ULN Other : No prior second malignancy past 10 year except carcinoma situ cervix basal squamous cell carcinoma skin No psychological , familial , sociological , geographical condition precludes study compliance Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Concurrent radiotherapy allow indicator lesion include irradiated field See Disease Characteristics Surgery : Not specify Other : No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>